Navigation Links
Alere Inc. Statement Amending Acceptance Condition to Axis-Shield Offer
Date:9/26/2011

s involved in the Offer disclaim any responsibility or liability for the violation of such restrictions by any person.

Neither the US Securities and Exchange Commission nor any securities commission of a state in the United States has (a) approved or disapproved of the Offer; (b) passed upon the merits or fairness of the Offer; or (c) passed upon the adequacy or accuracy of the disclosure in this press release. Any representation to the contrary is a criminal offence in the United States.

The availability of the Offer to Axis-Shield Shareholders who are not resident in the United Kingdom may be affected by the laws of the relevant jurisdictions in which they are resident. Persons who are not resident in the United Kingdom should inform themselves of, and observe, any applicable requirements.

Unless otherwise determined by Alere AS Holdings, this Announcement and the Offer is not, and will not be made, directly or indirectly, in or into any jurisdiction where to do so would violate the laws in that jurisdiction (a "Restricted Jurisdiction") or by use of any means or instrumentality (including, without limitation, telex, facsimile transmission, telephone, internet or other forms of electronic communication) of interstate or foreign commerce, or of any facility of a national securities exchange of any Restricted Jurisdiction. Unless so determined by Alere AS Holdings, the Offer will not be capable of acceptance by any such use, means or instrumentality or facility of any Restricted Jurisdiction.

Copies of this Announcement will not be, and must not be, directly or indirectly, mailed or otherwise forwarded (including, without limitation, by telex, facsimile transmission, telephone, internet or other forms of electronic communication), distributed or sent in, into or from any Restricted Jurisdiction.

Alere AS Holdings reserves the right to elect, with the consent of the Panel (where necessary), to impl
'/>"/>

SOURCE Alere Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Inverness Medical Innovations Changes Name to Alere
2. Alere Inc. Schedules Conference Call for 10:00 a.m. ET July 28, 2010 to Discuss Second Quarter 2010 Results
3. Alere and AirStrip Technologies - a Powerful Collaboration Brings Innovative Remote Patient Monitoring to Obstetrical Care
4. Alere Inc. Announces Offering of $350 Million of Senior Subordinated Notes
5. Alere Inc. Announces Pricing of Senior Subordinated Notes Offering; Offering Size Increased to $400.0 Million
6. Alere to Attend the Fifth Annual JMP Securities Healthcare Conference on September 28, 2010
7. Alere to Attend the Lazard Capital Markets 7th Annual Healthcare Conference on November 17, 2010
8. Alere Inc. Announces Fourth Quarter 2010 Results
9. Alere Previews Findings from Key Research Study on Medication Adherence at Integrated Benefits Institute Conference
10. Alere Earns NCQA Health Information Products Certification for Health Information Line
11. Alere Inc. Announces First Quarter 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013   Life Technologies ... a licensing agreement granting Suzhou Ribo Life Sciences ... siRNA therapeutics in China ... formulate proprietary siRNA molecules in combination with Invivofectamine® ... address human diseases with high unmet medical need ...
(Date:6/19/2013)... , 19. Juni 2013 ... mit der Entwicklung von SCS microRESIST™, ... in der Beschichtung mit Parylene gelungen ... von biokompatiblem Parylene mit antimikrobiellen Eigenschaften ... schädlicher Mikroorganismen auf beschichteten medizinischen Geräten. ...
(Date:6/18/2013)... , June 18, 2013  Intercept Pharmaceuticals, Inc.  ... company focused on the development and commercialization of novel ... announced the pricing of an underwritten public offering of ... offering price of $33.01 per share.  In addition, Intercept ... up to an additional 259,500 shares of common stock. ...
Breaking Medicine Technology:Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
... All pre-specified subset analyses of progression-free survival,in the ... in,relative risk of disease progression for patients receiving,satraplatin. ... as presence or absence of pain. -- The ... - radiologic,progression and pain progression - were each ...
... ,Abstracts: 2000, 2002 , CHICAGO/DARMSTADT, Germany, June 4, ... today at the American Society of,Clinical Oncology (ASCO) ... cilengitide in patients with newly diagnosed,glioblastoma – a ... highly selective integrin inhibitor targeting the,tumor and its ...
Cached Medicine Technology:Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 2Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 3Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 4Merck at ASCO 2007: Encouraging Results in Progression-Free,Survival in Patients With Aggressive Brain Tumors (glioblastoma),Using Cilengitide in Phase I/IIa Study 5
(Date:6/19/2013)... 19, 2013 Brightree LLC , ... software solutions for the post-acute care industry, has been ranked ... the Healthcare Informatics 100 (HCI 100) list. This ... the U.S. in terms of revenue during the last fiscal ... rate of 85% annually, and the company has built its ...
(Date:6/19/2013)... Boca Raton, FL (PRWEB) June 19, 2013 ... spoke about the positive changes and growth that has occurred ... his nationwide travel club. , Shuman said, "Travel Services has ... program to heights beyond belief. Membership is up, even ... agents to meet the demands of members." , Having been ...
(Date:6/19/2013)... disease Amyotrophic lateral sclerosis (ALS), also known as Lou ... can be classified into four distinct stages, report pathologists ... of Pennsylvania in the Annals of Neurology . ... tissues shows, for the first time, how the fatal ... the central nervous system to other regions of brain ...
(Date:6/19/2013)... derived from a naturally occurring compound (apocynin), has ... with Parkinson,s Disease symptoms by preventing deficits in ... the May 28, 2013 edition of ... postdoctoral fellow at the Medical College of Wisconsin ... Balaraman Kalyanaraman, Ph.D., Harry R. & Angeline ...
(Date:6/19/2013)... Imprivata ®, a leading global provider ... Imprivata OneSign ® leads the single sign-on (SSO) category ... & Services report . CIOs and other healthcare executives ... performance of its products and the quality of its ... is integral to their long-term healthcare IT strategy. ...
Breaking Medicine News(10 mins):Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Former Owner Eric Shuman Endorses New Owners and Changes Made in Last Year Since Shuman Sold Travel Services Center at Member Conference 2Health News:Staging system in ALS shows potential tracks of disease progression, Penn study finds 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3
... one of the worlds leading causes of blindness could be ... discovery here. , In experiments with laboratory rats, scientists at ... a potential new therapy for uveitis the inflammation of ... the outer surface of the eyeball and includes the iris. ...
... ... Sept. 28 Registered nurses at up to 16,Northern California hospitals, ... strike in October that could involve up to 5,500 RNs at,facilities ... Yuba City and Marysville. Strike notices are being sent today ...
... VAWith extensively drug-resistant tuberculosis, life-threatening drug-resistant respiratory and ... headlines, infectious diseases physicians are applauding Rep. Jim ... introducing H.R. 3697, the Strategies To Address Antimicrobial ... The STAAR Act has the potential to save ...
... 28 Healthcare,Technologies Ltd. (NASDAQ: HCTL ), ... meeting of its shareholders for the approval of,the ... Bioventures,Inc. and Gamida for Life B.V., originally scheduled ... to allow shareholders additional time to fully consider,the ...
... Curtail Infant,Deaths, WASHINGTON, Sept. 28 The ... new civil rights issue" and,requires a revised set ... by the Joint Center for Political and Economic,Studies., ... to Love: Infant Mortality,Commission, which was established by ...
... program is improving air quality, agency claims , , FRIDAY, ... (NOx) from power plants, cars and other industry are ... for less ozone and therefore less smog and healthier ... NOx Budget Trading Program annual report from the U.S. ...
Cached Medicine News:Health News:New discovery may improve treatment of one of the world's leading causes of blindness 2Health News:RNs to Announce October Strike of 5,500 Nurses 2Health News:Infectious diseases experts applaud bill against 'bad bugs' 2Health News:Healthcare Technologies to Reschedule the Shareholders Meeting to Approve the NexGen Biofuels Transaction 2Health News:Healthcare Technologies to Reschedule the Shareholders Meeting to Approve the NexGen Biofuels Transaction 3Health News:Joint Center Says New Approach Required to Reduce Black Infant Mortality 2Health News:Joint Center Says New Approach Required to Reduce Black Infant Mortality 3Health News:Less Smog Now in Eastern U.S.: EPA 2
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
... BD Beaver Clear Cornea Incision System ... specifically for the Cataract surgeon. The System ... an alternative to costly diamond knives. ... shield that is designed to both protects ...
... Carl Zeiss Meditec's technological expertise ... retinal disease became apparent with revolutionary ... system. Now, with the introduction of ... expertise is being applied to high-resolution, ...
... the eyeglasses in the EZ Meter and ... automatically display the measurement results on its ... detection to data printout makes this the ... and private offices.,In addition to being extremely ...
Medicine Products: